Id: | acc0486 |
Group: | 2sens |
Protein: | STAT1 |
Gene Symbol: | STAT1 |
Protein Id: | P42224 |
Protein Name: | STAT1_HUMAN |
PTM: | phosphorylation |
Site: | Ser727 |
Site Sequence: | QTTDNLLPMSPEEFDEVSRIV |
Disease Category: | Cancer |
Disease: | Leukemia |
Disease Subtype: | AML |
Disease Cellline: | SET-2 |
Disease Info: | |
Drug: | cortistatin A |
Drug Info: | "Cortistatin A is a natural steroidal alkaloid isolated from marine sponges, primarily studied for its potent anti-angiogenic and antiproliferative activities in preclinical research, particularly in the context of cancer therapeutics." |
Effect: | modulate |
Effect Info: | "Cortistatin A effectively inhibits the phosphorylation of STAT1(S727) in a dose-dependent manner, thereby suppressing the growth of JAK2-mutated AML." |
Note: | |
Score: | 4.0 |
Pubmed(PMID): | 29239838 |
Sentence Index: | 29239838_3-4 |
Sentence: | We previously demonstrated that Mediator kinase inhibitor cortistatin A (CA) reduced proliferation of JAK2-mutant AML in vitro and in vivo and also suppressed CDK8-dependent phosphorylation of STAT1 at serine 727. Here we report that phosphorylation of STAT1 S727 promotes the proliferation of AML cells with JAK-STAT pathway activation. |
Sequence & Structure:
MSQWYELQQLDSKFLEQVHQLYDDSFPMEIRQYLAQWLEKQDWEHAANDVSFATIRFHDLLSQLDDQYSRFSLENNFLLQHNIRKSKRNLQDNFQEDPIQMSMIIYSCLKEERKILENAQRFNQAQSGNIQSTVMLDKQKELDSKVRNVKDKVMCIEHEIKSLEDLQDEYDFKCKTLQNREHETNGVAKSDQKQEQLLLKKMYLMLDNKRKEVVHKIIELLNVTELTQNALINDELVEWKRRQQSACIGGPPNACLDQLQNWFTIVAESLQQVRQQLKKLEELEQKYTYEHDPITKNKQVLWDRTFSLFQQLIQSSFVVERQPCMPTHPQRPLVLKTGVQFTVKLRLLVKLQELNYNLKVKVLFDKDVNERNTVKGFRKFNILGTHTKVMNMEESTNGSLAAEFRHLQLKEQKNAGTRTNEGPLIVTEELHSLSFETQLCQPGLVIDLETTSLPVVVISNVSQLPSGWASILWYNMLVAEPRNLSFFLTPPCARWAQLSEVLSWQFSSVTKRGLNVDQLNMLGEKLLGPNASPDGLIPWTRFCKENINDKNFPFWLWIESILELIKKHLLPLWNDGCIMGFISKERERALLKDQQPGTFLLRFSESSREGAITFTWVERSQNGGEPDFHAVEPYTKKELSAVTFPDIIRNYKVMAAENIPENPLKYLYPNIDKDHAFGKYYSRPKEAPEPMELDGPKGTGYIKTELISVSEVHPSRLQTTDNLLPMSPEEFDEVSRIVGSVEFDSMMNTV
Select PDB:
No data.
Protein Tractability:
source: Open TargetsPTM Intensity:
source: CPTACSTAT1-Ser727 | |
---|---|
Cancer | Intensity |
BRCA | 0.237 |
COAD | 0.528 |
HGSC | -2.013 |
ccRCC | -0.034 |
GBM | 1.48 |
HNSC | 0.35 |
LUAD | 0.26 |
LUSC | 0.618 |
non_ccRCC | -1.678 |
PDAC | 0.093 |
UCEC | 0.159 |
PTM-Disease Association:
source: PTMDResidue | Position | State | Disease | Class | PMID |
---|---|---|---|---|---|
S | 727 | U | Colorectal cancer | Phosphorylation | 33747209 |
S | 727 | U | Nephroblastoma | Phosphorylation | 16799645 |
State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.
PTM-Drug Perturbation Response:
source: DecryptMProtein | Gene | PTM | Position | Modified sequence | Cell | Drug | pEC50 | Regulation | Experiment |
---|---|---|---|---|---|---|---|---|---|
P42224 | STAT1 | P | Ser727 | LQTTDNLLPMS(ph)PEEFDEVSR | ARH-77 | Rituximab | -3.8138 | - | |
P42224 | STAT1 | P | Ser727 | LQTTDNLLPMS(ph)PEEFDEVSR | ARH-77 | Rituximab | -1.2378 | - | |
P42224 | STAT1 | P | Ser727 | LQTTDNLLPMS(ph)PEEFDEVSR | ARH-77 | Rituximab | -4.0059 | - | |
P42224 | STAT1 | P | Ser727 | LQTTDNLLPMS(ph)PEEFDEVSR | ARH-77 | Rituximab | -3.4501 | - | |
P42224 | STAT1 | P | Ser727 | LQTTDNLLPMS(ph)PEEFDEVSR | ARH-77 | Rituximab | -3.7206 | - | |
P42224 | STAT1 | P | Ser727 | LQTTDNLLPMS(ph)PEEFDEVSR | ARH-77 | Rituximab | -3.8972 | - | |
P42224 | STAT1 | P | Ser727 | LQTTDNLLPMS(ph)PEEFDEVSR | ARH-77 | Rituximab | -1.2209 | - | |
P42224 | STAT1 | P | Ser727 | LQTTDNLLPMS(ph)PEEFDEVSR | ARH-77 | Rituximab | -1.2194 | - |
pEC50 Note: pEC50 is the negative logarithm of EC50 (half-maximal effective concentration, dosage unit Mol), calculated as pEC50 = -log10(EC50), which quantifies the potency of a drug or compound.
Function score:
source: funscoRNo data.